dated source and formulation scope
Keep tablet restrictions and document dates separate
The 2007 mirror and separately retrieved Ferring tablet label agree on selected renal restrictions. This is limited concordance, not proof of complete current labeling.
What to reconcilePreserve the dated source and conventional-tablet scope. Do not copy injectable or sublingual schedules.
2 source identities and dates
GlobalRPh RX List - DDAVP tabletsGlobalRPh-hosted RX List | Source revision: 7/2007; page also prints FDA revision 2007-10-26
DDAVP conventional oral tablets for central DI or primary nocturnal enuresis; not NOCDURNA sublingual, NOCTIVA nasal or injectable desmopressin.
Read this stored source Desmopressin - DDAVP oral tabletsDailyMed / Ferring Pharmaceuticals Inc. | Source revision: Source revision date not established in selected retrieval.
DDAVP conventional oral tablets for central DI or primary nocturnal enuresis; not NOCDURNA sublingual, NOCTIVA nasal or injectable desmopressin.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
monitoring scope
NOCDURNA: renal eligibility does not remove sodium safeguards
A renal no-adjustment statement above the cutoff coexists with hyponatremia precautions, monitoring and fluid restriction.
What to reconcileConfirm the sublingual product, sodium assessment and full contraindications, rather than relying on renal eligibility alone.
1 source identities and dates
GlobalRPh RX List - NOCDURNAGlobalRPh-hosted RX List | Source revision: RX page prints June 2018.
Desmopressin - NOCDURNA sublingual tablets; selected source sections, not a full prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.
formulation scope
NOCTIVA and NOCDURNA: route and contraindication scope differ
The nasal and sublingual products have separate instructions, including different printed heart-failure wording. A shared ingredient does not make them interchangeable.
What to reconcileConfirm exact route, product, current availability and full warning scope; do not transfer strengths or monitoring assumptions.
1 source identities and dates
GlobalRPh RX List - NOCTIVAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Desmopressin - NOCTIVA nasal spray; selected source sections, not a full prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.
label version and indication
A newer indication changes the renal initiation schedule
The May 2024 mirror addresses MDD. The August 2026 official label includes a separate lower-strength starting schedule for Alzheimer-dementia-associated agitation in moderate impairment.
What to reconcileConfirm indication and the exact combination strength. Read the official indication-specific renal subsection rather than importing general twice-daily titration.
2 source identities and dates
GlobalRPh RX List - AUVELITYGlobalRPh-hosted RX List | Source revision: 5/2024
AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.
Read this stored source DailyMed / AUVELITY exact product labelDailyMed / Axsome Therapeutics, Inc. | Source revision: 8/2026
AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
dialysis context
Dry weight and post-dialyzer timing are part of the regimen
KORSUVA uses target dry body weight and is administered after blood stops passing through the dialyzer. A missed session resumes at the next HD session.
What to reconcileDo not use predialysis fluid-loaded weight by default, give before completion of dialysis, or extrapolate to PD/non-HD CKD.
1 source identities and dates
GlobalRPh RX List - KORSUVAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adults with moderate-to-severe CKD-associated pruritus receiving hemodialysis.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
source scope and renal guidance
Before use: Digoxin - intravenous injection
Renal function alone is insufficient: use the route-specific matrix with lean body weight, clinical response, interactions, electrolytes and measured concentrations. Digoxin immune Fab is an antidote, not another digoxin formulation.
What to reconcileUse the IV matrix and full injection precautions; keep dose units in mcg and separate this from immune Fab.
2 source identities and dates
Digoxin - intravenous injectionDailyMed / NLM exact product labeling | Source revision: 6/2025
Adult IV maintenance excerpt from label Table 3; no pediatric dosing or loading algorithm.
Read this stored source GlobalRPh RX List - LANOXIN injectionGlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
Adult IV digoxin; pediatric and IM material on the source page is outside this summary.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
source scope and renal guidance
Before use: Digoxin - oral tablets
Renal function alone is insufficient: use the route-specific matrix with lean body weight, clinical response, interactions, electrolytes and measured concentrations. Digoxin immune Fab is an antidote, not another digoxin formulation. SPS describes when to measure levels, not universal daily laboratory testing.
What to reconcileSeparate serum concentration monitoring from routine renal/electrolyte checks; the 7-day post-change advice is limited to normal renal function.
3 source identities and dates
Digoxin - oral tabletsDailyMed / NLM exact product labeling | Source revision: 6/2024
Adult oral maintenance excerpt from label Table 3; no pediatric dosing or loading algorithm.
Read this stored source GlobalRPh RX List - LANOXIN tabletsGlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval
Adult oral digoxin; selected maintenance and monitoring text.
Read this stored source NHS SPS - digoxin monitoringNHS Specialist Pharmacy Service | Source revision: 27 December 2023
UK professional monitoring guidance; not a US product-label dose table.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
monitoring timing and assay interference
Preserve early potassium monitoring and distinguish free from total digoxin
The RX general paragraph says especially after the first several hours; its laboratory paragraph and February 2026 manufacturer label say during the first several hours.
What to reconcileDo not delay early potassium surveillance. Prolonged renal observation and free-digoxin assessment are separate from a misleading post-Fab total concentration.
2 source identities and dates
GlobalRPh RX List - DIGIFABGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.
Read this stored source Digoxin immune Fab (ovine) - DIGIFAB intravenous antidoteSalvagenix Inc. / manufacturer prescribing information | Source revision: 02/2026
DIGIFAB for life-threatening or potentially life-threatening digoxin toxicity; this renal-monitoring record is not an antidote dose calculator.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.0.
pharmacokinetic interpretation
Unchanged active-metabolite exposure does not remove the restriction
VUMERITY's active-metabolite exposure finding differs from its inactive-metabolite accumulation concern. The source still does not recommend use in moderate or severe renal impairment.
What to reconcileUse the explicit product recommendation rather than inferring no adjustment from the active-metabolite study alone. Do not borrow another fumarate product's renal policy.
1 source identities and dates
GlobalRPh RX List - VumerityGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VUMERITY delayed-release product; not interchangeable renal evidence for other fumarates.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.
evidence limit
MODEYSO: a renal-study dose is not a recommended renal dose
The selected PK study used a dose described as a fraction of the maximum recommended dose. That study design does not itself establish a renal prescription.
What to reconcileDo not turn the study amount or exposure ratio into a dose-adjustment algorithm.
1 source identities and dates
GlobalRPh RX List - MODEYSOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Dordaviprone - MODEYSO; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
source scope and renal guidanceNew v6.8
Before use: Dorzolamide 2% ophthalmic solution (Trusopt)
Historical label retained as a dated renal restriction; current marketed-product reconciliation is pending.
What to reconcileCheck the current exact ophthalmic product and renal status. Do not substitute the timolol combination or infer a dialysis schedule.
2 source identities and dates
Dorzolamide 2% ophthalmic solution (Trusopt) - selected label sectionsFDA / historical TRUSOPT label supplement | Source revision: 12/2020 (historical supplement)
Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).
Read this stored source Dorzolamide 2% ophthalmic solution (Trusopt) - RX mirror renal summaryGlobalRPh RX List / product-label mirror | Source revision: 12/2020
Single-ingredient TRUSOPT dorzolamide 2% ophthalmic solution (20 mg/mL). Not dorzolamide/timolol (Cosopt).
Read this stored source Selected source reconciliation only; independent clinician adjudication pending. Added: v6.8.
restriction vs monitoring
Potassium monitoring does not override a renal contraindication
The source describes a renal restriction and separate monitoring for otherwise eligible patients using potassium-raising medicines.
What to reconcileDo not turn the monitoring instruction into permission for a contraindicated renal population.
1 source identities and dates
GlobalRPh RX List - SLYNDGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Drospirenone-only SLYND oral contraceptive; not drospirenone/ethinyl estradiol combinations.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.3.
dose table scope
IWILFIN: use the published renal BSA table, not automatic per-dose halving
The official table includes an asymmetric morning/evening band. Its tablet schedule is stored as published rather than generated by dividing each usual administration.
What to reconcileConfirm BSA band and source renal units; apply the table rather than a percentage alone.
2 source identities and dates
GlobalRPh RX List - IWILFINGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult and pediatric high-risk neuroblastoma relapse-risk reduction after qualifying prior therapy; oral IWILFIN, not topical eflornithine.
Read this stored source Eflornithine - IWILFINDailyMed / USWM, LLC | Source revision: Prescribing information revised 11/2024.
Adult and pediatric high-risk neuroblastoma indication; oral tablets. BSA and renal-function assessment are distinct inputs.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.
population scope
CERDELGA: CYP2D6 status changes renal eligibility
The same renal-function value can lead to different eligibility for an extensive versus intermediate or poor CYP2D6 metabolizer.
What to reconcileEstablish the source-defined metabolizer category and review interacting drugs and hepatic status before using a renal band.
1 source identities and dates
GlobalRPh RX List - CERDELGAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult Gaucher disease type 1; eligibility depends on CYP2D6 metabolizer status as well as renal, hepatic and interacting-drug context.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
source scope
LYNKUET: retrieved PK text is not the missing renal prescribing section
Only selected renal pharmacokinetic material was established in this retrieval; the referenced prescribing subsection was not available.
What to reconcileTreat the stored card as limited evidence, not a renal dosing or dialysis recommendation.
1 source identities and dates
GlobalRPh RX List - LYNKUETGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Elinzanetant - LYNKUET; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
label vs professional guidance
GENVOYA: label restriction versus qualified NIH panel practice
The RX label does not recommend use at CrCl 15-29. NIH retains that recommendation but notes some Panel members continue full-dose FTC in this range to retain the fixed-dose regimen, with insufficient evidence for or against that practice.
What to reconcileThis is not blanket approval, a new-start rule, or permission to adjust a fixed-dose component independently. Obtain HIV specialist input and document the rationale.
2 source identities and dates
GlobalRPh RX List - GenvoyaGlobalRPh-hosted RX List | Source revision: September 2021, as printed in retrieved RX source.
GENVOYA fixed-dose oral HIV regimen; adults and qualifying pediatric patients, with adult-only chronic-HD provision.
Read this stored source NIH adult ARV renal table: GENVOYANIH ClinicalInfo HIV guidelines | Source revision: Source revision date not established in selected retrieval.
NIH adult/adolescent ARV table; GENVOYA row and its qualified FTC footnote only.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.